Mylan Specialty, a subsidiary of Mylan, and Pfizer have signed a licensing contract for EpiPen Injection 0.3/0.15mg in Japan.
Under the license agreement, Pfizer will have the exclusive rights to market and sell EpiPen Injection 0.3/0.15mg in Japan, which is the only approved epinephrine auto-injector in the country.
Mylan chief executive officer Heather Bresch the Japanese Ministry of Health, Labour and Welfare approved National Health Insurance price listing for EpiPen Injection. The financial terms of the agreement were kept confidential.
"We have built on this positive momentum by recently launching our next-generation EpiPen Injection in Japan," Bresch added.
The products, known as EpiPen (epinephrine) 0.3mg and EpiPen Jr (epinephrine) 0.15mg Auto-Injectors, in the US, are indicated for self-administration for the emergency treatment of life-threatening allergic reactions (anaphylaxis) caused by allergens, exercise or unknown triggers.
Pfizer Japan president Ichiro Umeda said, "This agreement will help us to better address this important public health issue in Japan -- from improving awareness and preparedness, to expanding access to treatment -- through Pfizer's existing commercial infrastructure and market expertise."
